Schnitzler Syndrome (SchS) is a rare disorder, with ∼350 cases reported in the literature, characterized by a neutrophilic urticarial dermatosis and monoclonal gammopathy (IgM in more than 90% of the cases), associated with clinical and biological signs of inflammation.1–3 In 2013, Lipsker, Schnitzler, and other experts met and proposed the Strasbourg diagnostic criteria, which are widely used today to diagnose SchS (Table 1).1,4 We report a case of a man with a clinical and laboratory diagnosis of SchS in Brazil.

A 67-year-old man presented to our department with recurrent pruritic, not painful, urticaria-like lesions on the extremities and the trunk (Fig. 1). The lesions resolved within 24 hours without leaving behind dusky hyperpigmentation. He had intermittent fever of up to 39 °C, generalized arthralgia, and fatigue. The inflammatory episodes lasted for 2–5 days with severe general impairment. The patient suffered outbreaks with variable intensity on almost a monthly basis over the past fifteen years. Histopathology of lesional skin showed a perivascular and interstitial polymorphonuclear infiltrate, described as consistent with the diagnosis of urticarial lesions and compatible with SchS (Fig. 2).

Fig. 1.

Urticarial lesions on the trunk and left arm.

(0.09MB).

Fig. 2.

Inflammatory cells around superficial dermal vessels with neutrophils (A, Hematoxylin & eosin, ×100) also observed in the interstitial space among collagen fibers (B, Hematoxylin & eosin, ×400).

(0.79MB).

Laboratory investigations revealed leucocytosis (up to 21.000 mm3, ref 4000–11600 mm3), an elevated ESR (120 mm/hr; 0∼20 mm/hr), and increased IgM levels (2550 mg/dL; 46∼260 mg/dL) in serum protein electrophoresis (Fig. 3). In the bone scan, there is a slight asymmetry of uptake in the tibias, slightly greater on the left. Bone marrow biopsy was performed with a negative cytogenetic study for lymphoproliferative diseases. Based on these clinical and laboratory findings, he was diagnosed with Schnitzler Syndrome.

Fig. 3.

Increased IgM levels in serum protein electrophoresis test.

(0.05MB).

He was started on a high-dose corticosteroid, NSAIDs, and antihistamines with partial remission of his symptoms.

There are a few cases reported in Latin America and in general, it is underdiagnosed despite the well-established diagnostic criteria, but the pathogenesis is unknown.5

The major complication is hematological malignancy, with lymphoproliferative disorder occurring in about 10%‒20% of patients.5,6 In addition to chronic spontaneous urticaria, other differential diagnoses should be considered (Table 2).7

At present, for patients with CRP < 3 mg/dL, treatment options include, colchicine, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and hydroxychloroquine.1,2 Corticosteroids has a moderate effect and antihistamine therapy has no effect.8 According to Simon et al., the efficacy of colchicine is only 25%, but based on the benefit/risk ratio, colchicine is recommended as the first choice of treatment.9 Experts recommend the use of anakinra (IL-1 block) in more symptomatic patients, such as Erythrocyte Sedimentation Rate (ESR) and CRP above the upper limit of normal (CRP > 3 mg/dL).1

Treatment with corticosteroids, NSAIDs, and antihistamines is symptomatic and unsatisfactory.9 Anakinra (IL-1-neutralizing) is the choice drug. The effect of inhibition of IL-1 has led to new expectations, but there is currently unavailable in Brazil. An alternative drug could be canakinumab, a human anti-IL-1β monoclonal antibody aiming at the neutralization of 1β signaling.10

In patients presenting with chronic urticaria associated with signs of systemic inflammation, this rare and debilitating syndrome should be considered. Early treatment can improve patient's quality of life and disease prognosis.